Circulating Tumor DNA (ctDNA) for Plasma Genotyping and Disease Monitoring in ALK-Positive Anaplastic Lymphoma (ALK+ALCL): A Proof of Concept Study

间变性淋巴瘤激酶 微小残留病 克里唑蒂尼 碱性抑制剂 间变性大细胞淋巴瘤 数字聚合酶链反应 医学 淋巴瘤 内科学 ROS1型 肿瘤科 癌症研究 生物 聚合酶链反应 癌症 基因 白血病 肺癌 遗传学 腺癌 恶性胸腔积液
作者
Damien Vasseur,Samuel Abbou,Ludovic Lacroix,Laurence Lamant,Pata-Merci Noémie,David Sibon,Francesco Facchinetti,Marc Deloger,Floriane Brayé,Véronique Minard‐Colin,Laurence Brugières,Étienne Rouleau,Luc Friboulet,Charlotte Rigaud
出处
期刊:Blood [Elsevier BV]
卷期号:142 (Supplement 1): 4375-4375
标识
DOI:10.1182/blood-2023-185808
摘要

Introduction Circulating tumor DNA (ctDNA) detection has not been reported yet in ALK-positive anaplastic large cell lymphoma (ALK+ALCL), a rare aggressive non-Hodgkin lymphoma with a peak incidence in children, adolescents and young adults. In this study, we aimed to evaluate whether ctDNA can be detected, characterized and used to monitor minimal residual disease (MRD) in ALK+ALCL. Patients and Methods Plasma samples were collected from 23 French patients diagnosed with ALK+ALCL between November 2020 and March 2023. Based on cell-free DNA (cfDNA) extracted from plasma, we performed shallow whole genome sequencing (shWGS) and a comprehensive genomic profiling (CGP) of more than 500 genes covered at a median depth of over 3000 unique reads to assess ctDNA content. In this study, we defined samples as positive if they had a tumor fraction over 3%, evaluated by shWGS analysis, or if ALK rearrangements were identified using CGP. Additionally, ALK rearrangement genomic breakpoint were defined by CGP analysis. For each patient, specific digital droplet PCR (ddPCR) assays were designed based on the identified breakpoints to monitor ctDNA content during the ALK+ALCL disease follow-up. Results The median age of patients at the time of diagnosis was 13 years (range: 4-54). Sixteen patients, (69.6%) received at least one ALK tyrosine kinase inhibitor (TKI). A total of 80 plasma samples were collected at various time points from the 23 patients, with a median of 3 samples per patient (range: 1 - 20). Four samples failed for DNA extraction, resulting in 76 samples available for molecular analysis Of the 76 samples, 43 (56.6%) were analyzed using shWGS, 19 (25%) using CGP among which, 14 were analyzed using both techniques. CGP was found to be a more sensitive method for detecting ctDNA in ALK+ALCL compared to shWGS, with 12 out of 14 samples (85.7%) tested positive with CGP, compared to 5 out of 14 samples (35.7%) with shWGS (p<0.01). Of the 19 samples tested with CGP, ALK rearrangement was identified in 14 samples (73.7%), with NPM1:: ALK fusion detected in 11 samples, and ATIC:: ALK, TRAF1:: ALK and EEF1G:: ALK detected in one sample each. The average tumor mutational burden was low, with 5.3 mutations per megabase (mut/Mb) (range: 0-14.5 mut/Mb). No microsatellite instability was detected. Amplification of MDM4 and MYC genes was observed in three patients each. ANKRD26 was the most frequently mutated gene in the study, with four patients affected. LRP1B, epigenetic modifiers such as EP300 and KMT2A, and TP53 were mutated in three patients each. Interestingly, CGP allowed the identification of the ALK:c.3520T>C;p.(Phe1174Leu) mutation in a plasma sample collected during disease progression while the patient was on long lasting crizotinib therapy. Finally, we monitored MRD, based on ctDNA detection in 49 samples from 12 patients using ddPCR assays. Our results were compared with the established gold standard for MRD monitoring in ALK+ALCL, i.e. RT-PCR on circulating cells performed on the same samples. The ddPCR assay showed a 87% sensitivity, 100% specificity, 100% positive predictive value, and 83% negative predictive value. However, four samples had false-negative results due to pre-analytical sampling issues. These samples had been stored at room temperature without undergoing centrifugation for more than 24 hours. Conclusion To date, this study is the first to report on the feasibility and clinical value of ctDNA for the management of ALK+ALCL patients. CGP demonstrated high sensitivity in detecting ctDNA, identifying the genomic breakpoint within the ALK gene and, for the first time in ALK+ALCL, detecting resistance mutations to ALK TKI. Additionally, our unique patient-specific ddPCR approach was proven to be a cost-effective method for MRD monitoring. Altogether, these findings serve as a proof-of-concept for the development of ctDNA techniques in the clinical management of ALK+ALCL.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
满座完成签到,获得积分10
刚刚
杨羕完成签到,获得积分10
1秒前
五六七完成签到,获得积分10
1秒前
周少完成签到,获得积分10
1秒前
兴奋的若菱完成签到 ,获得积分10
1秒前
幸福广山完成签到,获得积分10
3秒前
HMethod完成签到 ,获得积分10
5秒前
Y123完成签到,获得积分10
5秒前
6秒前
ersan完成签到,获得积分10
7秒前
Hello应助nkmenghan采纳,获得30
8秒前
8秒前
8秒前
粗心的听安完成签到,获得积分10
8秒前
念姬完成签到 ,获得积分10
9秒前
量子星尘发布了新的文献求助10
9秒前
10秒前
11秒前
指哪打哪完成签到,获得积分10
11秒前
11秒前
静静子发布了新的文献求助100
12秒前
Ray完成签到 ,获得积分10
13秒前
文静的天蓝完成签到,获得积分10
13秒前
tszjw168完成签到 ,获得积分10
14秒前
手打鱼丸完成签到 ,获得积分10
15秒前
体贴凌柏发布了新的文献求助10
15秒前
开心快乐发大财完成签到,获得积分10
17秒前
萌萌哒完成签到,获得积分10
17秒前
小龅牙吖完成签到,获得积分10
17秒前
Propitious完成签到,获得积分10
18秒前
徐先生1106完成签到,获得积分10
18秒前
Epiphany完成签到,获得积分10
19秒前
舒心的久完成签到 ,获得积分10
19秒前
闻巷雨完成签到 ,获得积分10
21秒前
北风完成签到,获得积分10
22秒前
xliiii完成签到,获得积分10
22秒前
时光倒流的鱼完成签到,获得积分10
23秒前
LL完成签到,获得积分10
23秒前
李李完成签到,获得积分20
23秒前
雨无意完成签到,获得积分10
24秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038303
求助须知:如何正确求助?哪些是违规求助? 3576013
关于积分的说明 11374210
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029